Answers are grounded in this paper and cite their sources.
Observational analysis identifies doxorubicin's antiviral mechanism in drug-resistant HSV-1, highlighting safety concerns for oncolytic therapies.
This study identifies PI3K-AKT pathway inhibition as a novel host-directed antiviral mechanism underlying doxorubicin's activity against HSV-1, demonstrates its synergistic potential with nucleoside analogs, and provides mechanistic insight into raising concerns over oncolytic HSV-based therapies. Collectively, these findings highlight the potential of localized, host-targeted strategies for managing drug-resistant HSV-1 infections.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: